Pharmaceutical company Acino, part of Arcera, has resumed operations at its Kyiv-based Farma Start plant after it was damaged by shelling in 2025, investing around UAH 500 million in reconstruction, modernization, and upgraded production safety. After nine months of downtime, the facility has restarted operations and is already running at full capacity.
From an economic perspective, the plant’s recovery signals the willingness of international pharmaceutical businesses to continue investing in Ukraine despite elevated risks. The investment was directed not only toward repairs, but also toward equipment upgrades and staff training, strengthening the long-term efficiency and resilience of production.
The company is gradually returning its products to the market. Some medicines are already being supplied to pharmacies, while the full product range is expected to be restored in the second quarter of 2026. During the shutdown, supplies were maintained through existing inventories, although shortages of certain medicines highlighted the market’s vulnerability to stoppages at major manufacturers. With the plant back at full utilization, the risk of supply disruptions is expected to decline.
Farma Start is one of the key players in Ukraine’s pharmaceutical market, with annual production capacity of up to 2 billion tablets and capsules. Its restoration is therefore important for stabilizing medicine supply, supporting employment, and sustaining tax revenues.
Financially, the company felt the impact of the shutdown. Revenue in 2025 declined to UAH 1.9 billion from UAH 2.3 billion a year earlier, while net profit fell to UAH 332.7 million from UAH 761 million. The restoration investment is viewed as a strategic step toward returning to growth and strengthening the company’s market position.
